2. Membrane Transporter/Ion Channel TGF-beta/Smad Epigenetics PI3K/Akt/mTOR Apoptosis Neuronal Signaling Vitamin D Related/Nuclear Receptor
  3. Aquaporin PKC Akt PI3K Apoptosis Monoamine Oxidase Pregnane X Receptor (PXR)
  4. Bacopaside I

Bacopaside I  (Synonyms: バコパシドI)

製品番号: HY-N4246 純度: 99.20%
COA 取扱説明書 Technical Support

Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Bacopaside I

Bacopaside I 構造式

CAS 番号 : 382148-47-2

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 625 在庫あり
Solution
10 mM * 1 mL in DMSO USD 625 在庫あり
Solid
5 mg $290 在庫あり
10 mg $470 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Other Forms of Bacopaside I:

Bacopaside I 関連抗体

Top Publications Citing Use of Products

PKC アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

Akt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Akt Akt1 Akt2 Akt3

PI3K アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

Monoamine Oxidase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
MAO-A MAO-B

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases[1][2][3][4].
IC50 & Target

MAO-A

 

体外実験

Bacopaside I (117-178 μM; 50 mins-2 h) potently and selectively inhibits AQP1-mediated osmotic water permeability in Xenopus laevis oocytes with an IC50 of 117 μM; Bacopaside I shows no activity against AQP4[1].
Bacopaside I (50-100 μM; 2 h) inhibits cGMP-dependent ion conductance of AQP1 in Xenopus laevis oocytes, and the blocking effect at 100 μM is stronger than that at 50 μM after 2 h of incubation[1].
Bacopaside I (48-50 μM; 24 h) inhibits the migration of HT29 colon cancer cells with high AQP1 expression, with an IC50 of 48 μM, and impairs the directional motility of the cells[1].
Bacopaside I (50-75 μM; 24 h) shows no cytotoxicity against HT29 colon cancer cells at concentrations up to 75 μM after 24 h of incubation[1].
Treatment with Bacopaside I (5-10 μM; 3-4 d) for 3 days reduces the proliferative activity of MDA-MB-231, T47D, MCF7 and BT-474 breast cancer cell lines; treatment for 4 days decreases the migratory capacity of breast cancer cell lines[2].
Combination treatment with Bacopaside I (5-10 μM; 24 h) and Bacopaside II reduces the transcript expression of AQP1 in MDA-MB-231 breast cancer cells, with an IC50 of 13 μM for inhibiting its activity[2].
Bacopaside I (administered at 5-25 μM for a total of 60 min, with treatment initiated before and maintained during 45 min of OGD) potently protects organotypic hippocampal slice cultures against OGD-induced neuronal injury by inhibiting apoptosis and necrosis, and the protective activity at 25 μM is superior to that at 5 μM[3].
Bacopaside I (administered at 25 μM before and during 45 minutes of OGD treatment, with a total intervention duration of 60 min) exerts neuroprotective effects against OGD-induced injury in organotypic hippocampal slice cultures. This effect depends on the PKC and PI3K/Akt signaling pathways, but is independent of the ERK signaling pathway or cholinergic receptor activation[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bacopaside I 関連抗体

Cell Migration Assay[1]

Cell Line: AQP1-high-expressing human HT29 colon cancer cells
Concentration: 48 μM (IC50 for migration inhibition); 50 μM
Incubation Time: 24 h
Result: Dose-dependently inhibited HT29 cell migration measured by wound closure, with an IC50 of 48 μM.
Significantly reduced HT29 cell migration into the wound area after 24 h incubation.
Induced compressed, non-directional movement trajectories and shorter mean total distance traveled by cells over 24 h compared to vehicle-treated cells.

Cell Viability Assay[2]

Cell Line: MDA-MB-231, T47D, MCF7, BT-474 breast cancer cell lines
Concentration: IC50 values
Incubation Time: 24 h
Result: Potently reduced cell viability with half maximal inhibitory concentrations (IC50) of 99 μM (95% CI 91-109) for MDA-MB-231, 89 μM (95% CI 73-109) for T47D, 83 μM (95% CI 79-87) for MCF7, and 59 μM (95% CI 56-63) for BT-474.

Real Time qPCR[2]

Cell Line: MDA-MB-231, T47D, BT-474 breast cancer cell lines
Concentration: 5 μM (in combination with 2.5 μM or 5 μM Bacopaside II); 10 μM (in combination with 2.5 μM Bacopaside II)
Incubation Time: 24 h
Result: Reduced AQP1 transcript expression by 1.8-fold relative to vehicle (p = 0.004) in MDA-MB-231 cells treated with 5 μM Bacopaside I + 2.5 μM Bacopaside II.
Reduced AQP1 transcript expression by 2.5-fold relative to vehicle (p < 0.0001) in MDA-MB-231 cells treated with 5 μM Bacopaside I + 5 μM Bacopaside II.
Showed no significant effect on AQP1 transcript expression in T47D or BT-474 cells.

Cell Viability Assay[2]

Cell Line: MDA-MB-231 breast cancer cell line
Concentration: 13 μM (in combination with 2.5 μM Bacopaside II)
Incubation Time: 24 h
Result: Exhibited an IC50 of 13 μM (95% CI 10-16 μM) in combination with 2.5 μM Bacopaside II, representing a synergistic interaction with a combination index (CIx) of 0.270 (95% CI 0.240-0.301).
体内実験

Bacopaside I (50 mg/kg; oral; daily; 7 days) causes no adverse effects in Swiss-albino mice[2].
Bacopaside I (oral route) exerts neuroprotective effects in rats with cerebral ischemia-induced injury by reducing neurological deficits, infarct volume, and edema, and by normalizing brain ATP, antioxidant enzyme, ATPase, and MDA levels[4].
Bacopaside I exhibits antidepressant-like activity in CUMS-exposed mice by reversing hypothalamic-pituitary-adrenal (HPA) axis hyperactivity[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss-albino mice[2]
Dosage: 50 mg/kg
Administration: oral; daily; 7 days
Result: Showed no adverse effects.
分子量

979.13

分子式

C46H74O20S
CAS 番号
Appearance

Solid

Color

Off-white to light yellow

SMILES

C[C@]12[C@@]34[C@@](CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](O[C@@]6([H])[C@@H]([C@H]([C@@H](O)CO6)O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)COS(=O)(O)=O)O[C@]8([H])O[C@@H](CO)[C@H](O)[C@H]8O)CC5)C)([H])CC2)C)([H])[C@]9([H])[C@@](OC4)(OC[C@@H](C=C(C)C)[C@@]9(O)C)C3
Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
体外: 

DMSO : 100 mg/mL (102.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.0213 mL 5.1066 mL 10.2131 mL
5 mM 0.2043 mL 1.0213 mL 2.0426 mL
10 mM 0.1021 mL 0.5107 mL 1.0213 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.55 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.55 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.0213 mL 5.1066 mL 10.2131 mL 25.5329 mL
5 mM 0.2043 mL 1.0213 mL 2.0426 mL 5.1066 mL
10 mM 0.1021 mL 0.5107 mL 1.0213 mL 2.5533 mL
15 mM 0.0681 mL 0.3404 mL 0.6809 mL 1.7022 mL
20 mM 0.0511 mL 0.2553 mL 0.5107 mL 1.2766 mL
25 mM 0.0409 mL 0.2043 mL 0.4085 mL 1.0213 mL
30 mM 0.0340 mL 0.1702 mL 0.3404 mL 0.8511 mL
40 mM 0.0255 mL 0.1277 mL 0.2553 mL 0.6383 mL
50 mM 0.0204 mL 0.1021 mL 0.2043 mL 0.5107 mL
60 mM 0.0170 mL 0.0851 mL 0.1702 mL 0.4255 mL
80 mM 0.0128 mL 0.0638 mL 0.1277 mL 0.3192 mL
100 mM 0.0102 mL 0.0511 mL 0.1021 mL 0.2553 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bacopaside I Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bacopaside I382148-47-2AquaporinPKCAktPI3KApoptosisMonoamine OxidasePregnane X Receptor (PXR)AQPProtein kinase CPKBProtein kinase BPhosphoinositide 3-kinaseMAOPregnane X ReceptorAkt pathwayXenopus laevis oocytesneuronal necrosisprotein kinase C (PKC)breast cancer cell linesAQP4colon cancer cellsaquaporin-1 (AQP1)phosphoinositide 3-kinase (PI3K)HT29 colon cancer cellsInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Bacopaside I
製品番号:
HY-N4246
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.